Subsense, a neurotechnology company developing the first non-surgical, nanoparticle-based Brain-Computer Interface (BCI), announced it emerged from stealth to formally reveal its efforts in the emerging field of non-invasive brain connectivity. The company also revealed its funding details.
The company was co-founded by neurotech entrepreneur Tetiana Aleksandrova and serial entrepreneur Artem Sokolov. And Subsense has raised $17 million in seed funding led by Sokolov’s Golden Falcon Capital to accelerate the development of bidirectional nanoparticle-based technologies that connect the human brain with external sources.
Subsense is collaborating with a consortium of leading international neurological research institutions, including UC Santa Cruz and ETH Zurich, Switzerland’s Federal Institute of Technology.
With targeted neural stimulation and precise monitoring via nanoparticles, Subsense is developing therapeutics for patients with neurological conditions such as Parkinson’s, Alzheimer’s, epilepsy, depression, strokes, chronic pain, and more.
The company is also targeting more expansive applications for later stages like
1.) Sensorimotor recovery of vision, hearing and movement
2.) Inner speech decoding and thought translation
3.) Integration with AI by merging brain and artificial neural networks
4.) External memory as an instant backup and extended capacity
5.) Mental health regulation – happiness monitoring and control
6.) Appetite control – identification and managing of regulatory mechanisms.
